Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future

查看全文 作　　者：Peter [1]Jenner

机构地区：[1]Neurodegenerative Diseases Research Group,Institute of Pharmaceutical Sciences,Faculty of Health Sciences and Medicine,King’s College,London SE11UL,UK

出　　处：《Translational Neurodegeneration》索引2015年第4卷第1期,共9页

摘　　要：The problems associated with the pharmacological treatment of the later stages of Parkinson’s disease(PD)remain those seen over many years.These centre on a loss of drug effect(‘wearing off’)with disease progression,the occurrence of dyskinesia,notably with L-dopa use and the appearance of non-motor symptoms that are largely refractory to dopaminergic medication.Treatment strategies in late PD have been dominated by the use of drug combinations and the subtle manipulation of drug dosage.However,change is occurring as the understanding of the basis of motor complications and fluctuations and non-motor symptoms improves.New pharmacological options are expanding with the advent of longer acting versions of existing dopaminergic drugs,new drug delivery systems and the introduction of non-dopaminergic agents able to manipulate motor function both within the basal ganglia and in other brain regions.Non-dopaminergic agents are also being investigated for the treatment of dyskinesia and for the relief of non-motor symptoms.However,while therapy continues to improve,the treatment of late stage PD remains problematic with non-motor symptoms dominating the unmet need in this patient group. 关键词：PHARMACOLOGICAL DOSAGE EXPANDING

相关文献

参考文献（99）
引证文献（8）
耦合文献（0）

参考文献(99)

引证文献(8)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future

参考文献(99)

引证文献(8)

用户提示